Clinical Trials Logo

Refractory Osteosarcoma clinical trials

View clinical trials related to Refractory Osteosarcoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04661852 Completed - Clinical trials for Refractory Osteosarcoma

Cabozantinib With Topotecan-Cyclophosphamide

Start date: December 23, 2020
Phase: Phase 1
Study type: Interventional

This research study is a clinical trial of a new combination of drugs as a possible treatment for relapsed/refractory Ewing sarcoma and/or osteosarcoma. - The names of the drugs are: - Cabozantinib - Topotecan - Cyclophosphamide - The names of the non-investigational supportive care drugs are: - Filgrastim, pegfilgrastim, or a related growth factor.

NCT ID: NCT02470091 Completed - Clinical trials for Recurrent Osteosarcoma

Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma

Start date: November 21, 2015
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well denosumab works in treating patients with osteosarcoma that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as denosumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

NCT ID: NCT02304458 Completed - Metastatic Melanoma Clinical Trials

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Start date: March 30, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent) or do not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether nivolumab works better alone or with ipilimumab in treating patients with recurrent or refractory solid tumors or sarcomas.